Cargando…
Tumor necrosis factor as a pharmacological target
As indicated by its name, tumor necrosis factor (TNF), cloned in 1985, was originally described as a macrophage-derived endogenous mediator that can induce hemorrhagic necrosis of solid tumors and kill some tumor cell lines in vitro. Unfortunately, its promising use as an anticancer agent was biased...
Autores principales: | Ghezzi, Pietro, Cerami, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Humana Press
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101943/ https://www.ncbi.nlm.nih.gov/pubmed/16230774 http://dx.doi.org/10.1385/MB:31:3:239 |
Ejemplares similares
-
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014) -
Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α
por: Corti, Angelo, et al.
Publicado: (2022) -
Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy
por: Bremer, Edwin
Publicado: (2013) -
Tumor Necrosis Factor: What Is in a Name?
por: Wang, Xinming, et al.
Publicado: (2022) -
Role of the Interaction of Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors 1 and 2 in Bone-Related Cells
por: Kitaura, Hideki, et al.
Publicado: (2022)